TITLE

Review: Adding cytotoxic drugs to a chemotherapy regimen increases tumor response rates and toxicity, but not survival in metastatic breast cancer

AUTHOR(S)
Khatcheressian, James; Smith, Thomas J.
PUB. DATE
January 2007
SOURCE
ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article cites a study conducted by researcher D. Jones and colleagues on the addition of cytotoxic drugs to a chemotherapy regimen in women with breast cancer. Clinical trials were performed that compared an existing chemotherapy regimen of 2 drugs with the same regimen and 1 additional drug in women receiving chemotherapy. The study concluded that the addition of a cytotoxic drug does not improve progression-free or overall survival, but increases the tumor response rates.
ACCESSION #
23847335

 

Related Articles

  • American Pharmaceutical's ABI-007 effective in breast cancer patients resistant to taxane therapy.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p6 

    Reports that American Pharmaceutical Partners has released findings from some of the patients enrolled in a phase II, metastatic breast cancer trial of ABI-007, a novel cremophor-free protein engineered nanoparticle paclitaxel. Frequency of administration of ABI-007 without steroid pretreatment;...

  • Bristol-Myers compound shows anti-cancer activity in phase II trials.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p7 

    Reports study findings showing that BMS-247550, an investigational tubulin polymerizing agent under development by Bristol-Myers, has demonstrated activity in metastatic breast cancer and non-small lung cancer. Components and mechanism of action of BMS-247500; Description of interim results from...

  • Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary†‡. Chuang, E.; Wiener, N.; Christos, P.; Kessler, R.; Cobham, M.; Donovan, D.; Goldberg, G. L.; Caputo, T.; Doyle, A.; Vahdat, L.; Sparano, J. A. // Annals of Oncology;Oct2010, Vol. 21 Issue 10, p2075 

    Background: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with...

  • Onyx Soars as Nexavar Hits Goal in Phase II.  // Bioworld Week;7/27/2009, Vol. 17 Issue 30, p4 

    The article reports that Onyx Pharmaceuticals Inc.'s share has increased after its multikinase inhibitor Nexavar met the primary endpoint in a Phase II trial. It notes that the result drove the company's stock up 6.03 dollars, closing July 22, 2009 at 34.72 dollars. The data reveals that the...

  • BREAST CANCER'S 'NEW ERA' Noonan, David; Carmichael, Mary; Barrett, Jennifer // Newsweek (Atlantic Edition);10/20/2003 (Atlantic Edition), Vol. 142 Issue 16, p89 

    Discusses an international clinical trial in breast cancer research that was stopped early because the drug being tested showed dramatic potential in reducing the risk of relapse. Finding that letrozole reduced the risk of recurrence in older women by 43%; Option that letrozole offers in...

  • BREAST CANCER'S 'NEW ERA' Noonan, David; Carmichael, Mary; Barrett, Jennifer // Newsweek (Pacific Edition);10/20/2003 (Pacific Edition), Vol. 142 Issue 16, p61 

    Discusses an international clinical trial in breast cancer research that was stopped early because the drug being tested showed dramatic potential in reducing the risk of relapse. Finding that letrozole reduced the risk of recurrence in older women by 43%; Option that letrozole offers in...

  • BREAST CANCER'S 'NEW ERA' Noonan, David; Carmichael, Mary; Barrett, Jennifer // Newsweek;10/20/2003, Vol. 142 Issue 16, p67 

    Discusses an international clinical trial in breast cancer research that was stopped early because the drug being tested showed dramatic potential in reducing the risk of relapse. Finding that letrozole reduced the risk of recurrence in older women by 43%; Option that letrozole offers in...

  • Genta begins study of Genasense in patients with advanced breast cancer.  // PharmaWatch: Cancer;July 2003, Vol. 2 Issue 7, p7 

    Reports that Genta has initiated a clinical trial with its lead anticancer drug, Genasense, in patients with advanced breast cancer. Evaluation of the safety and efficacy of Genasense in combination with Aventis' Taxotere and doxorubicin, two standard chemotherapy drugs; Mechanism of action of...

  • Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. Frances, N.; Claret, L.; Bruno, R.; Iliadis, A. // Cancer Chemotherapy & Pharmacology;Dec2011, Vol. 68 Issue 6, p1413 

    Purpose: Most of the cancer chemotherapy treatments employ drugs in combination. For combination treatments, it is relevant to assess interaction between two or more anticancer agents used in clinics. Based on clinical data and using modeling techniques, the work analyzes the pharmacodynamic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics